Immune Design said an interim analysis of its ongoing, randomized phase II trial showed that NY-ESO-1+ soft tissue sarcoma patients receiving the combination of CMB305 and Genentech’s checkpoint inhibitor, atezolizumab (Tecentriq), experienced greater clinical benefit and immune response than those receiving atezolizumab alone.
Soon after he was diagnosed with a dedifferentiated liposarcoma, C. Norman Coleman reached out to The Cancer Letter and the Cancer History Project to initiate a series of interviews about his life and career.
